AN2 Therapeutics, Inc.
ANTX
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.55% | -4.73% | 1.10% | 5.89% | -2.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.52% | -21.66% | 2.32% | 25.11% | 42.03% |
| Operating Income | 33.52% | 21.66% | -2.32% | -25.11% | -42.03% |
| Income Before Tax | 31.31% | 20.72% | -1.71% | -19.06% | -35.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.31% | 20.72% | -1.71% | -19.06% | -35.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.31% | 20.72% | -1.71% | -19.06% | -35.79% |
| EBIT | 33.52% | 21.66% | -2.32% | -25.11% | -42.03% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.39% | 38.98% | 28.86% | 19.18% | -2.98% |
| Normalized Basic EPS | 44.28% | 41.64% | 31.48% | 19.18% | -2.98% |
| EPS Diluted | 41.39% | 38.98% | 28.86% | 19.18% | -2.98% |
| Normalized Diluted EPS | 44.28% | 41.64% | 31.48% | 19.18% | -2.98% |
| Average Basic Shares Outstanding | 14.30% | 26.57% | 42.06% | 48.19% | 35.29% |
| Average Diluted Shares Outstanding | 14.30% | 26.57% | 42.06% | 48.19% | 35.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |